2023-07-11 09:16:46 ET
- BioRestorative Therapies ( NASDAQ: BRTX ) has entered into a definitive agreement with several accredited and institutional investors for the sale of 685,033 shares of the Co.’s common stock at an offering price of $3.03/share in a registered direct offering.
- The gross proceeds of the offering will be ~$2.1M.
- The Co. intends to use the net proceeds for its clinical trials with respect to its lead cell therapy candidate, BRTX-100, pre-clinical research and development with respect to its metabolic ThermoStem Program and for general corporate purposes and working capital.
- The closing of the offering is expected to take place on or about July 13, 2023.
For further details see:
BioRestorative to sell 685,033 shares at $3.03 in registered direct offering